Home
/
AMICUS THERAPEUTICS, INC.
/
Financials
/
Quarterly
AMICUS THERAPEUTICS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that AMICUS THERAPEUTICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$16.70M
May 9, 2018
Q1
2018
Mar 31, 2017
$4.17M
May 9, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$169.06M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$154.69M
Jul 31, 2025
Q1
2025
Mar 31, 2025
$125.25M
May 1, 2025
Q3
2025
Sep 30, 2024
$141.52M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$126.67M
Jul 31, 2025
Q1
2025
Mar 31, 2024
$110.40M
May 1, 2025
Q3
2024
Sep 30, 2023
$103.50M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$94.50M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$86.27M
May 9, 2024
Q3
2023
Sep 30, 2022
$81.69M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$80.73M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$78.72M
May 10, 2023
Q3
2022
Sep 30, 2021
$79.55M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$77.41M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$66.40M
May 10, 2022
Q3
2021
Sep 30, 2020
$67.44M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$62.35M
Aug 5, 2021
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2015
Sep 30, 2014
$293.0K
Nov 4, 2015
Q2
2015
Jun 30, 2014
$475.0K
Aug 5, 2015
Q1
2015
Mar 31, 2014
$456.0K
May 5, 2015
Q3
2014
Sep 30, 2013
$39.0K
Nov 6, 2014
Q2
2013
Jun 30, 2013
$121.88M
Aug 7, 2013
Q1
2013
Mar 31, 2013
$121.88M
May 9, 2013
Q3
2013
Sep 30, 2012
$18.41M
Nov 12, 2013
Q2
2013
Jun 30, 2012
$10.64M
Aug 7, 2013
Q1
2013
Mar 31, 2012
$7.77M
May 9, 2013
Q3
2012
Sep 30, 2011
$5.80M
Nov 6, 2012
Q2
2012
Jun 30, 2011
$4.04M
Aug 8, 2012
Q1
2012
Mar 31, 2011
$5.97M
May 11, 2012
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$17.31M
Nov 4, 2025
Q2
2025
Jun 30, 2025
($24.42M)
Jul 31, 2025
Q1
2025
Mar 31, 2025
($21.69M)
May 1, 2025
Q3
2025
Sep 30, 2024
($6.73M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($15.70M)
Jul 31, 2025
Q1
2025
Mar 31, 2024
($48.42M)
May 1, 2025
Q3
2024
Sep 30, 2023
($21.58M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($43.23M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($52.93M)
May 9, 2024
Q3
2023
Sep 30, 2022
($33.29M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($62.16M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($85.26M)
May 10, 2023
Q3
2022
Sep 30, 2021
($50.29M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($51.23M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($65.66M)
May 10, 2022
Q3
2021
Sep 30, 2020
($64.01M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($52.49M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($88.95M)
May 10, 2021
Q3
2020
Sep 30, 2019
($61.81M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($84.55M)
Aug 10, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$34.27M
Nov 4, 2025
Q2
2025
Jun 30, 2025
($9.47M)
Jul 31, 2025
Q1
2025
Mar 31, 2025
($7.95M)
May 1, 2025
Q3
2025
Sep 30, 2024
$21.66M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$14.97M
Jul 31, 2025
Q1
2025
Mar 31, 2024
($27.72M)
May 1, 2025
Q3
2024
Sep 30, 2023
($17.02M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($18.86M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($37.64M)
May 9, 2024
Q3
2023
Sep 30, 2022
($33.84M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($60.61M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($75.34M)
May 10, 2023
Q3
2022
Sep 30, 2021
($42.40M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($38.83M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($53.06M)
May 10, 2022
Q3
2021
Sep 30, 2020
($52.76M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($51.35M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($78.06M)
May 10, 2021
Q3
2020
Sep 30, 2019
($57.31M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($76.43M)
Aug 10, 2020